Understanding dendritic cell immunotherapy in ovarian cancer
作者： Maureen L. Drakes , Patrick J. Stiff
DOI: 10.1080/14737140.2016.1178576
关键词: Dc vaccine 、 Internal medicine 、 Ovarian cancer 、 Dendritic cell 、 Medicine 、 Immunotherapy 、 Immunology 、 T cell immunity 、 Disease 、 Drug resistance 、 Oncology 、 Clinical trial
摘要: ABSTRACTIntroduction: Approximately eighty percent of patients with ovarian cancer are diagnosed advanced disease. Even cutting edge surgical techniques and the best regimens standard therapies most relapse die drug resistant disease within five years diagnosis. Dendritic cell (DC) immunotherapy can induce anti-tumor T immunity in holds great potential era modern anti-cancer treatment.Areas Covered: This review outlines critical factors regulating outcome DC cancer, summarizes important findings clinical trials, discusses new directions which may improve effectiveness immunotherapy.Expert Commentary: Administration vaccines other forms enhance efficacy these treatments, ultimately increasing cures for this
sci-hub.se 参考文章(91)
An Coosemans, Thaïs Baert, Ignace Vergote, A view on dendritic cell immunotherapy in ovarian cancer: how far have we come? Facts, views & vision in obgyn. ,vol. 7, pp. 73- 78 ,(2015)
Sébastien Anguille, Heleen H. Van Acker, Johan Van den Bergh, Yannick Willemen, Herman Goossens, Viggo F. Van Tendeloo, Evelien L. Smits, Zwi N. Berneman, Eva Lion, Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner PLOS ONE. ,vol. 10, pp. e0123340- ,(2015) , 10.1371/JOURNAL.PONE.0123340
Jashodeep Datta, Erik Berk, Jessica A. Cintolo, Shuwen Xu, Robert E. Roses, Brian J. Czerniecki, Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy. Frontiers in Immunology. ,vol. 6, pp. 271- 271 ,(2015) , 10.3389/FIMMU.2015.00271
C.M.U. Hilkens, M.L. Kapsenberg, A. Snijders, F.G.M. Snijdewint, P. Kalinski, IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. Journal of Immunology. ,vol. 159, pp. 28- 35 ,(1997)
Stefaan W Van Gool, An Coosemans, Anke Vanderstraeten, Ignace Vergote, Philippe Moerman, Frédéric Amant, Zwi Berneman, Tina Verschuere, Sandra Tuyaerts, Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma. Anticancer Research. ,vol. 33, pp. 3855- 3859 ,(2013)
Christine V Ichim, Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy. Journal of Translational Medicine. ,vol. 3, pp. 8- 8 ,(2005) , 10.1186/1479-5876-3-8
Jitka Fucikova, Irena Moserova, Iva Truxova, Ivana Hermanova, Irena Vancurova, Simona Partlova, Anna Fialova, Ludek Sojka, Pierre-Francois Cartron, Milan Houska, Lukas Rob, Jirina Bartunkova, Radek Spisek, High hydrostatic pressure induces immunogenic cell death in human tumor cells. International Journal of Cancer. ,vol. 135, pp. 1165- 1177 ,(2014) , 10.1002/IJC.28766
Alfonso Martín-Fontecha, Antonio Lanzavecchia, Federica Sallusto, Dendritic Cell Migration to Peripheral Lymph Nodes Dendritic Cells. ,vol. 188, pp. 31- 49 ,(2009) , 10.1007/978-3-540-71029-5_2
Lawrence Fong, Dirk Brockstedt, Claudia Benike, Lijun Wu, Edgar G. Engleman, Dendritic Cells Injected Via Different Routes Induce Immunity in Cancer Patients Journal of Immunology. ,vol. 166, pp. 4254- 4259 ,(2001) , 10.4049/JIMMUNOL.166.6.4254
Andreas Draube, Nela Klein-González, Stefanie Mattheus, Corinne Brillant, Martin Hellmich, Andreas Engert, Michael von Bergwelt-Baildon, Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLOS ONE. ,vol. 6, ,(2011) , 10.1371/JOURNAL.PONE.0018801